A 4-part Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of M254 in Healthy Volunteers and in Patients With Immune Thrombocytopenic Purpura
Phase of Trial: Phase I/II
Latest Information Update: 23 Nov 2019
Price : $35 *
At a glance
- Drugs M-254 (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Momenta Pharmaceuticals
- 07 Nov 2019 According to a Momenta Pharmaceuticals media release, data from this study will be presented at the upcoming 61st American Society of Hematology (ASH) Annual Meeting and Exposition (Orlando, FL from 7th-10th Dec 2019).
- 02 Aug 2019 According to a Momenta Pharmaceuticals media release, Part A of this trial has been completed and the company expects to report preliminary data from this study in the first half of 2020.
- 09 Jun 2019 Planned number of patients changed from 70 to 93.